A recent review illustrates that metabolic crosstalk between tumor cells and immune cells shapes immunosuppressive tumor microenvironment in skin cancers, mediating the imbalance between pro-tumor and anti-tumor immunity and limiting durable clinical benefits of immunotherapy. Systematically dissecting metabolic reprogramming mechanisms and metabolic-targeted interventions provides theoretical support for advancing combinatorial metabolic-immune precision therapy for skin malignancies. Emerging metabolic intervention strategies, combined with novel analytical technologies and artificial intelligence, create promising avenues to overcome therapeutic bottlenecks in skin cancer treatment.

A new review in Advanced Cancer Research explains how artificial intelligence is being used across cancer drug discovery, from finding targets to designing and testing new drug candidates. The authors show where AI is already useful, and what still needs to improve before more AI-designed therapies can reach patients.A new review in Advanced Cancer Research explains how artificial intelligence is being used across cancer drug discovery, from finding targets to designing and testing new drug candidates. The authors show where AI is already useful, and what still needs to improve before more AI-designed therapies can reach patients.

Over the past 20 years, microrobots have moved from scientific vision toward biomedical reality. A perspective article by Bradley J. Nelson from ETH Zurich reviews how microrobots, typically ranging from about a millimeter down to a few microns in size, are being developed as intelligent microscale machines for future precision medicine. Inspired by the motility and adaptability of microorganisms, these systems are designed to function in low-Reynolds-number environments, where viscous forces dominate and conventional macroscale actuation principles are no longer applicable. The article discusses the physical constraints of microscale locomotion, major propulsion mechanisms, fabrication and material strategies, embodied intelligence, biomedical applications, and remaining translational challenges. It further suggests that advances in biocompatible materials, high-resolution imaging, magnetic navigation, and AI-driven control may support the future transition of microrobots from laboratory prototypes to clinically relevant tools for next-generation precision medicine.